【摘要】 目的观察雷珠单抗注射液治疗视网膜中央静脉阻塞(CRVO)伴有黄斑水肿的短期效果。方法收集2013年3月至2014年4月内蒙古自治区人民医院眼科门诊诊断为CRVO伴有黄斑水肿22例(22只眼)。诊断明确后玻璃体腔内注射0.05 ml雷珠单抗注射液,随后观察视力(包括矫正视力)、眼底、眼底荧光血管造影检查(FFA)和相干光断层扫描(OCT)4个月以上。黄斑水肿复发时,再次给与玻璃体注射雷珠单抗。结果患者平均观察时间为(6.3±2.5)个月,给药前的平均视力(log MAR值)为0.66±0.52,黄斑中心凹平均厚度为(689±175)μm。玻璃体腔内注射雷珠单抗注射液后平均视力(log MAR值)为:1周0.52±0.46,1个月0.48±0.46,2个月0.56±0.43,4个月后0.51±0.47与给药前比较有所提高,黄斑中心凹平均厚度在给药后1周、1个月、2个月、4个月后分别为(290±86)μm(P<0.01),(280±80)μm(P<0.01),(450±240)μm(P<0.01),(362±190)μm(P<0.01),与给药前比较得到了明显的改善。结论 CRVO继发黄斑水肿给予玻璃体注射雷珠单抗注射液,短期观察视力有所提高,黄斑水肿明显改善。更多还原

【Abstract】 Objective To observation the short-term effects of Lucentis intravitreal injection on macular edema due to central retinal vein occlusion( CRVO). Methods Twenty-two eyes of 22 patients with macular edema due to CRVO were treated in our hospital. Patients received intravitreal injection of 0. 05 ml Lucentis,and were followed with best-corrected visual acuity( BCVA),fluorescein angiography and central macular thickness( CMT; by optical coherence tomography) for at least 4 months. A second intravitreal injection was given when macular edema recurred during the follow-up period. Results The mean follow up was 6. 3 ± 2. 54 months. Before treatment the baseline BCVA( log MAR) and CMT were 0. 66 ± 0. 52 and 689 ± 175m,respectively. After treatment,mean BVCA significantly improved at 1 week( 0. 52± 0. 46),1 month( 0. 48 ± 0. 46),2 months( 0. 56 ± 0. 43),and 4 months( 0. 51 ± 0. 47). Mean CMT also decreased at 1 week( 290 ± 86m,P < 0. 01),1 month( 280 ± 80m,P < 0. 01),2 months( 450 ± 240m,P < 0. 01),and 4 months( 362 ± 190m,P < 0. 01),paralleled with the improvement of BCVA. Conclusion Intravitreal injection of Lucentis improves visual acuity and macular edema caused by CRVO.更多还原